--- title: "Sonoma Pharmaceuticals lifts at-the-market offering ceiling to $3,641,703" url: "https://aibio.space/news/sonoma-pharmaceuticals-lifts-market-offering-ceiling-3-641-703/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-06-18" section: "Company Updates" tickers: "NASDAQ:SNOA" source: "https://www.sec.gov/Archives/edgar/data/1367083/000168316826004975/sonoma_8k.htm" summary: "A prospectus supplement filed June 18, 2026 raises the aggregate offering price under the company's sales agreement with Ladenburg Thalmann to $3,641,703." --- By the aibio.space news desk. Sources - [Sonoma Pharmaceuticals, Inc. 8-K (2026-06-18)](https://www.sec.gov/Archives/edgar/data/1367083/000168316826004975/sonoma_8k.htm) - [Sonoma Pharmaceuticals, Inc. 10-K (2026-06-16): business](https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm) - [Sonoma Pharmaceuticals, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/) [SNOA](https://aibio.space/companies/sonoma-pharmaceuticals/) 2026-06-18 # Sonoma Pharmaceuticals lifts at-the-market offering ceiling to $3,641,703 Tickers [SNOA](https://aibio.space/companies/sonoma-pharmaceuticals/) A prospectus supplement filed June 18, 2026 raises the aggregate offering price under the company's sales agreement with Ladenburg Thalmann to $3,641,703. ## Key facts - **Company**: Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) - **News type**: Company Updates - **Primary source**: [Sonoma Pharmaceuticals, Inc. 8-K (2026-06-18)](https://www.sec.gov/Archives/edgar/data/1367083/000168316826004975/sonoma_8k.htm) *Reading a sequencing gel, 1980. Photo: Linda Bartlett, public domain, via Wikimedia Commons. The picture shows the field, not the companies named.* Sonoma Pharmaceuticals, Inc. filed a supplement to its prospectus supplement on June 18, 2026 that increases the aggregate offering price of common stock it may sell under its at-the-market sales agreement to $3,641,703. The [Form 8-K](https://www.sec.gov/Archives/edgar/data/1367083/000168316826004975/sonoma_8k.htm) filed the same day, signed by Chief Executive Officer Amy Trombly, reports the change under Items 8.01 and 9.01. ## The sales agreement Sonoma entered into an At Market Issuance Sales Agreement on September 26, 2025 with Ladenburg Thalmann & Co. Inc., which acts as agent. Under the agreement, the company may offer and sell shares of its common stock, par value $0.0001 per share, from time to time through Ladenburg, as agent. Sales are made under a registration statement on Form S-3, File No. 333-275311, which the U.S. Securities and Exchange Commission declared effective on November 20, 2023, and under a related prospectus supplement filed September 26, 2025. That prospectus supplement registered the sale of up to $2,070,463 of common stock. ## Sales so far and the higher ceiling From September 26, 2025 through the date of the filing, Sonoma sold an aggregate of 173,073 shares of common stock for an aggregate purchase price of $574,633 under the agreement. As of the filing date, the amount of common stock the company may offer under General Instruction I.B.6 of Form S-3 had increased to an aggregate offering price of $3,641,703. On June 18, 2026, the company filed the supplement to the prospectus supplement that increases the aggregate offering price to $3,641,703. That figure includes $1,495,830 of shares that were previously registered under the prospectus supplement but had not been sold. Polsinelli PC provided an opinion on the validity of the shares that may be issued under the agreement and the supplement, filed as Exhibit 5.1, with its consent included in Exhibit 23.1. ## Company background Sonoma describes its business as developing and producing stabilized hypochlorous acid products for wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its annual report on Form 10-K for the fiscal year ended March 31, 2026 says it sells products directly or through partners in over 55 countries. The dermatology line is one of the company's main areas. The annual report says those products are aimed at relieving pain and itch from skin irritations, managing scars, and managing symptoms of eczema and atopic dermatitis. The company relaunched direct sales of its prescription and office dispense dermatology products in the United States in December 2024. In Europe and the United Kingdom, the company has developed products to assist in the treatment of acne. The annual report says the company intends to keep seeking regulatory clearances for its products. ## Financial position According to the [XBRL financial data](https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/), revenue was $19.5 million for the fiscal year ended March 31, 2026, against $14.3 million for the year before. Net loss was $3.2 million in fiscal 2026 and $3.5 million in fiscal 2025, while cash from operations was negative $3.9 million in fiscal 2026 and negative $88,000 in fiscal 2025. The XBRL summary lists year-end cash and cash equivalents of $5.4 million for the fiscal year ended March 31, 2025. ## The cost to shareholders Any sales under the agreement go through Ladenburg as agent, within the higher ceiling, and each sale dilutes current holders. The 8-K does not say how much stock the company expects to sell, or when, and it describes no change to the September 2025 terms beyond the new price. The program has raised little so far: $574,633 since September 26, 2025, against cash used in operations of $3.9 million in fiscal 2026. The filing gives no reason for the larger ceiling. Revenue grew to $19.5 million, but the company remains loss-making. The annual report's claim that its products are clinically proven is the company's own. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story SNOA Sonoma Pharmaceuticals, Inc. NASDAQ ยท United States Open the starter desk ## More in Company Updates Company Updates ### [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/) Oct 29, 2026 Company Updates ### [Processa clears VT-7208 CSU IND and names a new executive chair](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/) Oct 29, 2026 Company Updates ### [Kiora in-licenses late-stage KIO-401 for retinal artery occlusion](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/) Oct 29, 2026 --- Source page: https://aibio.space/news/sonoma-pharmaceuticals-lifts-market-offering-ceiling-3-641-703/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sonoma Pharmaceuticals lifts at-the-market offering ceiling to $3,641,703", 2026-06-18, https://aibio.space/news/sonoma-pharmaceuticals-lifts-market-offering-ceiling-3-641-703/